RecruitingNCT07497867

Long-term Prospective Study of Korean CADASIL Patients

Long-term Prognosis of Korean Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy(CADASIL) Patients: A Multicenter Prospective Study

Sponsor

Jeju National University Hospital

Enrollment

500 participants

Start Date

Jul 10, 2023

Study Type

OBSERVATIONAL

Conditions

Cadasil Cerebral Autosomal Dominant Arteriopatie With Subcortical Infarcts and Leukoencephalopathy

Summary

K-CADASIL is a 10-year prospective study of 500 Korean patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a genetic brain disease that causes stroke and dementia. The investigators will track symptoms, brain scans, memory tests, and gene information to understand disease progression in Koreans and identify better treatments. Participants will visit clinics regularly for check-ups and blood tests. This study aims to help improve care for CADASIL patients and families worldwide.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with cadasil and cerebral autosomal dominant arteriopatie with subcortical infarcts and leukoencephalopathy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 19 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.